ClinicaliQ Trial Snapshot
- Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN — Recruiting • Phase III • NCT05755386.
- Iptacopan reduces kidney damage better than placebo in patients with a specific type of glomerulonephritis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis. Conditions: IC-MPGN Interventions: Placebo, iptacopan Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 106 participants